VIOLET AMIRJALALI: Open Payments
NPI 1558686659 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,238 in 176 payments from 38 companies in 2025. Trend: 2023 $3,535 · 2024 $3,846 · 2025 $3,238
Food & beverage: $3,230Education: $8
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 17 | $329 |
| Amgen Inc. | 18 | $307 |
| ABBVIE INC. | 14 | $207 |
| Bayer Healthcare Pharmaceuticals Inc. | 12 | $187 |
| Dexcom, Inc. | 8 | $170 |
| Xeris Pharmaceuticals, Inc. | 9 | $167 |
| RECORDATI_RARE_DISEASES_INC. | 16 | $141 |
| Almatica Pharma LLC | 6 | $138 |
| Tandem Diabetes Care, Inc. | 6 | $138 |
| Ascendis Pharma Endocrinology Inc | 10 | $137 |
Products named: Ozempic, REPATHA, Kerendia, Dexcom G6 Transmitter, TERIPARATIDE, JARDIANCE, GVOKE HYPOPEN, ISTURISA.
Industry payments across NV — which companies pay providers there.
